<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680314</url>
  </required_header>
  <id_info>
    <org_study_id>2015-5341</org_study_id>
    <nct_id>NCT02680314</nct_id>
  </id_info>
  <brief_title>Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?</brief_title>
  <official_title>Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether inducing labor with just one dose of&#xD;
      misoprostol, followed by treatment with oxytocin, will still be effective enough to increase&#xD;
      the chances of having a successful vaginal delivery as compared to using more than one dose&#xD;
      of misoprostol, followed by treatment with oxytocin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves a comparison of two different regimens of prostaglandin use for &quot;cervical&#xD;
      ripening&quot; prior to induction of labor. Women admitted to the hospital for induction of labor&#xD;
      who are found to have &quot;unripe&quot; cervixes at the time of admission, and who agree to&#xD;
      participate in the study will be randomly assigned to one of two treatment groups. In one&#xD;
      group, a single dose of 25 µcg of misoprostol will be administered vaginally and four hours&#xD;
      later oxytocin induction will be started if clinically indicated. In the second group of&#xD;
      women, repeat doses of misoprostol will be given every four hours up to six doses unless&#xD;
      labor or cervical ripening occurs sooner. At this point, oxytocin will be started as needed.&#xD;
      Success of vaginal delivery by 24 hours, time from initiation of protocol to delivery and&#xD;
      cesarean section rates will be compared. Complications such as postpartum hemorrhage,&#xD;
      episodes of tachysystole with fetal compromise and chorioamnionitis and endometritis will be&#xD;
      monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">June 16, 2021</completion_date>
  <primary_completion_date type="Actual">May 17, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Vaginal Delivery Within 24 Hours</measure>
    <time_frame>within 24 hours</time_frame>
    <description>To compare the rate of vaginal delivery within 24 hours in patients who receive a single dose of misoprostol versus those receiving multiple doses of this medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Interval From Initiation of Misoprostol to Delivery in Each Group</measure>
    <time_frame>within 24 hours from the initial intervention</time_frame>
    <description>To determine the interval from initiation of misoprostol to delivery in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Labor; Forced or Induced, Affecting Fetus or Newborn</condition>
  <arm_group>
    <arm_group_label>Single Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple doses of misoprostol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.</description>
    <arm_group_label>Multiple Dose</arm_group_label>
    <arm_group_label>Single Dose</arm_group_label>
    <other_name>cytotec, methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any pregnant woman undergoing induction of labor&#xD;
&#xD;
          -  Live singleton pregnancy ≥ 37 week gestation&#xD;
&#xD;
          -  Bishop score &lt; 6&#xD;
&#xD;
          -  Category I fetal heart rate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to vaginal delivery (e.g. vasa previa, placenta prevue,non-vertex&#xD;
             presentation, umbilical cord prolapse, and active genital herpes infection.)&#xD;
&#xD;
          -  Pregnancies complicated by major fetal anomalies&#xD;
&#xD;
          -  Any contraindication to the use of misoprostol, including&#xD;
&#xD;
          -  History of previous c-section or major uterine surgery&#xD;
&#xD;
          -  Prior allergic reaction&#xD;
&#xD;
          -  Category II or III fetal heart rate&#xD;
&#xD;
          -  Regular uterine contractions ≥ 3 in a 10-minute period persistent for at least 30&#xD;
             minutes&#xD;
&#xD;
          -  Estimated fetal weight &lt; 10 percentile&#xD;
&#xD;
          -  Premature rupture of membranes&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Women who do not have the capacity to consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Tropper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <results_first_submitted>June 16, 2021</results_first_submitted>
  <results_first_submitted_qc>July 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2021</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Peter S. Bernstein</investigator_full_name>
    <investigator_title>Prof., Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>unripe cervix</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02680314/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Dose</title>
          <description>single dose of misoprostol</description>
        </group>
        <group group_id="P2">
          <title>Multiple Dose</title>
          <description>multiple doses of misoprostol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Dose</title>
          <description>single dose of misoprostol&#xD;
Misoprostol: Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.</description>
        </group>
        <group group_id="B2">
          <title>Multiple Dose</title>
          <description>multiple doses of misoprostol&#xD;
Misoprostol: Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="243"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black/African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaginal Delivery Within 24 Hours</title>
        <description>To compare the rate of vaginal delivery within 24 hours in patients who receive a single dose of misoprostol versus those receiving multiple doses of this medication.</description>
        <time_frame>within 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose</title>
            <description>single dose of misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Multiple Dose</title>
            <description>multiple doses of misoprostol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaginal Delivery Within 24 Hours</title>
          <description>To compare the rate of vaginal delivery within 24 hours in patients who receive a single dose of misoprostol versus those receiving multiple doses of this medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Interval From Initiation of Misoprostol to Delivery in Each Group</title>
        <description>To determine the interval from initiation of misoprostol to delivery in each group</description>
        <time_frame>within 24 hours from the initial intervention</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Dose</title>
          <description>single dose of misoprostol</description>
        </group>
        <group group_id="E2">
          <title>Multiple Dose</title>
          <description>multiple doses of misoprostol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Bernstein, MD</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-904-2767</phone>
      <email>pbernste@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

